What is the recommended dosage frequency for meloxicam (nonsteroidal anti-inflammatory drug)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Meloxicam Dosage Frequency

Meloxicam is administered once daily, with a starting dose of 7.5 mg that can be increased to a maximum of 15 mg once daily if needed for adequate symptom control. 1, 2

Standard Dosing Regimen

  • Meloxicam should be taken as a single daily dose, not divided throughout the day 2
  • The initial dose is 7.5 mg once daily for most patients 1, 2
  • If 7.5 mg provides insufficient relief, the dose may be increased to 15 mg once daily 1, 2
  • The maximum recommended dose is 15 mg once daily 1

Special Population Considerations

Elderly Patients

  • Start with 7.5 mg once daily and maintain this as the maximum dose in elderly patients (over 59-75 years) 1, 2
  • Lower initial doses and slower titration are recommended due to increased risk of adverse events 1
  • The risk of gastrointestinal bleeding increases dramatically with age, from 1 in 2,100 in adults under 45 years to 1 in 110 in adults over 75 years 1

Patients with Renal Impairment

  • Avoid meloxicam entirely in patients with GFR < 30 mL/min/1.73 m² 1
  • Prolonged therapy is not recommended in patients with GFR < 60 mL/min/1.73 m² 1
  • Temporarily suspend meloxicam during intercurrent illness, planned IV radiocontrast administration, bowel preparation, or prior to major surgery 1

Duration and Monitoring

Treatment Duration Limits

  • Meloxicam should not be used continuously for more than 2-4 weeks without reassessment, as prolonged NSAID use significantly increases gastrointestinal, cardiovascular, and renal complications 1
  • For acute pain conditions, NSAID monotherapy should generally not exceed 1 month 1
  • Continuing NSAID monotherapy beyond 2 months is inappropriate for patients with active arthritis 1

Required Monitoring

  • Monitor renal function if treatment extends beyond 2 weeks, particularly in elderly patients or those with existing renal impairment 1
  • Blood pressure monitoring is warranted, as NSAIDs can increase blood pressure by approximately 5 mm Hg with continued use 1
  • Consider gastroprotection with proton pump inhibitors for patients requiring treatment beyond 2 weeks 1

Common Pitfalls to Avoid

  • Do not prescribe meloxicam more than once daily - the medication is specifically formulated for once-daily dosing 2
  • Do not continue monotherapy indefinitely without reassessing the need for alternative or adjunctive therapies 1
  • Do not ignore cardiovascular risk factors, as long-term use increases risk of cardiac ischemic events by 3.5 per 1,000 persons 1
  • Avoid combining with anticoagulants when possible, as this increases gastrointestinal bleeding risk five to six times 1
  • Do not use in combination with corticosteroids like prednisone without proton pump inhibitor prophylaxis, as this combination significantly increases gastrointestinal adverse events 3

Alternative Dosing Strategies

  • For step-by-step therapy, meloxicam may be given intramuscularly (1.5 mL) for 3-5 days, followed by transition to oral administration (7.5-15 mg once daily) for 14 days 4
  • Intravenous meloxicam (30 mg) has been studied for moderate to severe postoperative pain, though this is not standard outpatient dosing 4

References

Guideline

Meloxicam Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Meloxicam Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Concurrent Use of Meloxicam and Prednisone

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Meloxicam clinical effects].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.